Evidence map›Paper›PMID 41468548›Full record

Observational studyAntimicrobial agents and chemotherapy2026

Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study.

Nuo Xu, Yufei Shi, Gehang Ju, Xin Liu, Gangfeng Yan, Yi Zheng, Shuyu Hou, Xiaoqiang Xiang, Guoping Lu, Dongsheng Ouyang and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nuo Xu *Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.ORCID 0009-0003-3543-663X
Yufei Shi *Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.ORCID 0000-0002-9476-0312
Gehang JuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Xin LiuDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Gangfeng YanPediatric Intensive Care Unit, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Yi ZhengDMPK department, Suzhou Frontage New Drug Development Co.,Ltd, Suzhou, Jiangsu, China.
Shuyu HouDMPK department, Suzhou Frontage New Drug Development Co.,Ltd, Suzhou, Jiangsu, China.
Xiaoqiang XiangDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Guoping LuPediatric Intensive Care Unit, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Dongsheng OuyangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Xiao ZhuDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.ORCID 0000-0003-3295-619X
Yixue WangPediatric Intensive Care Unit, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.ORCID 0000-0002-2720-5415

Funding

Children's Hospital of Fudan University, China EKYX202417Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples FZJZ-202305National Natural Science Foundation of China 82204544Shanghai Municipal Health Commission Clinical Research Youth Project 20224Y0121
6 · The paper itself

Abstract

While caspofungin is increasingly used to treat invasive fungal infections in pediatric intensive care unit (PICU) patients, its pharmacokinetic profile in this population remains poorly understood, and current dosing regimens are not firmly supported by scientific evidence. This study aimed to characterize the population pharmacokinetics of caspofungin in critically ill children and to identify dosing strategies for optimal exposure. The prospective clinical study was conducted among pediatrics in PICU. Population pharmacokinetic analysis and Monte Carlo simulations were performed. A total of 138 plasma samples collected from 29 pediatric patients (0.33-16 years) were included in the final analysis. The two-compartment model with allometric scaling on body surface area (BSA, exponential 1 for volume of distribution and 0.66 for clearance) accurately described time courses of caspofungin. Extracorporeal membrane oxygenation (ECMO) significantly increased the central volume of distribution (effect coefficient 18.2). There was no significant difference in area under the concentration curve (AUC) between patients with and without ECMO support. Simulations demonstrated that tAUC

Indexed as

Antifungal AgentsCaspofunginAdolescentArea Under CurveChildChild, PreschoolChinaCritical IllnessEast Asian PeopleExtracorporeal Membrane OxygenationFemaleHumansInfantIntensive Care Units, PediatricMaleMicrobial Sensitivity TestsAntifungal AgentsCaspofungincaspofunginECMOintensive care unitspediatricspopulation pharmacokinetics

Identifiers

PMID41468548
PMCPMC12888871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.